Gilad Mamlok serves as the Chief Financial Officer at Protalix Biotherapeutics since August 2025, following a tenure in the same role at TytoCare and Sol-Gel, where Mamlok played a key role in the company's successful IPO in 2018. Mamlok's extensive experience includes positions at XYLO Technologies, Covidien (Medtronic Minimally Invasive Therapies Group), Given Imaging, MetaCure, Simbionix, and NiCE, showcasing expertise in financial leadership, strategic planning, fundraising, and corporate governance. Mamlok holds a PhD in Economics from the University of Rochester and two degrees from Tel Aviv University, including a Master's in Business/Managerial Economics and a Bachelor's in Economics.
This person is not in any teams
This person is not in any offices